Major Leadership Changes at Eli Lilly!

Global pharmaceutical giant Eli Lilly has recently seen frequent leadership appointments at its senior levels.

Appointment of the First Chief AI Officer, Ushering in a New Era of AI in Healthcare

On October 10, Eli Lilly announced the appointment of Thomas J. Fuchs as the company’s first Chief Artificial Intelligence Officer, effective from October 21, 2024. This decision not only signals Lilly’s deep commitment to the field of AI but also suggests that the healthcare industry may be moving towards a more intelligent future.

Thomas J. Fuchs has an extensive background in artificial intelligence and healthcare. Before joining Eli Lilly, he served as the Dean and founding Chair of the Department of Artificial Intelligence and Human Health at Mount Sinai, Director of the Hasso Plattner Institute for Digital Health at Mount Sinai, and Professor of AI and Computational Pathology at the Icahn School of Medicine at Mount Sinai. He has made significant contributions to integrating AI into healthcare research.

Under his leadership, Eli Lilly will launch a series of AI-related projects covering various aspects, including drug discovery and clinical trials. This transformation, which breaks away from traditional pharmaceutical models, will undoubtedly improve research and development efficiency, shorten time-to-market, and better serve patients, enhancing the quality of healthcare.

Eli Lilly China Management Team: Yan Qiong Appointed as Vice President of the Diabetes Business Unit

On October 9, Eli Lilly China President and General Manager Huzur Devletsah announced a significant management appointment. Effective October 10, Yan Qiong will serve as the Vice President of the Diabetes Business Unit and become a member of the Eli Lilly China management team, reporting directly to Huzur Devletsah. This appointment marks a critical step in Eli Lilly China’s new phase of business development.

Yan Qiong has a rich career background, having previously served as Senior Vice President in the field of oncology at Novartis, with extensive industry experience. After joining Eli Lilly, she will be responsible for driving the growth of Lilly's key product, Tirzepatide, and the metabolic product line in the Chinese market. This appointment not only reflects Eli Lilly’s focus on the Chinese market but also demonstrates the company’s ambition in the diabetes treatment field.

Yan Qiong’s addition will undoubtedly bring new energy and strategic perspective to Eli Lilly China, helping the company stand out in an increasingly competitive market environment.